Does Elementis plc’s Profit Warning Suggest Croda International plc Is The Better Buy?

Croda International Plc (LON: CRDA) has many advantages over smaller peer Elementis plc (LON: ELM).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares of Elementis (LSE: ELM) have slumped by as much as 13% in early trading today, after the company warned that it expects full-year earnings per share to miss market expectations. 

A significant reduction in oil projects within North America was the reason given for the warning.

Sales of chemical additives used in oil sector projects are expected to be around 30% lower this year than the previous year. 

What’s more, Elementis’ personal care business is facing challenges in the Latin America market, where it has been impacted by local currency weaknesses. Further, demand in China for the group’s coatings additives weakened in the second quarter. 

However, personal care sales are running ahead of forecasts in other markets, which will help the division meet its targets for the year. 

Lowering expectations 

Before today’s warning, City analysts had been expecting Elementis to report earnings per share of 16.1p for 2015.  

And before today’s decline, these projections meant that the company was trading at a forward P/E of 19.5; a premium valuation that left little room for error. 

Unfortunately, analysts have not yet had time to factor today’s news into their earnings projections for Elementis. So, it’s impossible to place a value on the company at present. 

That said, Elementis does support a dividend yield of 4.2%, which appears safe for the time being — Elementis has a cash-rich balance sheet and remains cash generative. 

A better pick 

There’s no denying that Elementis has racked up an impressive performance during the past five years. Since 2010, the company’s shares have gained 332%, and earnings per share have jumped by 70%. 

Still, as today’s update shows, the company’s outlook is at the mercy of outside factors that it can’t control. Being a relatively small player in such a big market means that Elementis’ trading is bound to be volatile from time to time. 

On the other hand, Croda (LSE: CRDA) is one of the world’s largest speciality chemical producers and the group’s size gives it an enormous advantage. 

Outperforming

Croda’s shares have returned 642% since June 2005. Over the same period, Elementis has only notched up a gain of 443%. Elementis suffered during the financial crisis while Croda surged ahead.

That being said, Croda’s profit growth has lagged that of Elementis during the past five years. Croda’s earnings per share have only expanded 42% since 2010. 

But Croda has a defensive element to the business. The company’s life sciences or healthcare division is growing at a double-digit clip and is unlikely to be affected by global economic trends.

Croda’s healthcare sales increased by 15.8% during the first half of its financial year thanks to better-than-expected sales of its pharmaceutical grade Omega-3. Increased sales of high purity excipients (a substance that serves as a delivery medium for a drug) also helped boost sales. 

Not cheap

With its leading position in the chemicals industry, Croda isn’t cheap. The company currently trades at a forward P/E of 21 and supports a dividend yield of 2.5%.

Nevertheless, sometimes you have to pay a premium for quality. Croda’s steady growth and defensive nature are worth paying for. 

City analysts are forecasting earnings per share growth of 7% per annum is expected for the next two years. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended Elementis. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »